The Society of Gynecologic Oncology and ASCCP endorse this document. USPSTF Cervical Cancer Screening Recommendations for Average-Risk. As with the updates, the new ACS/ASCCP/ASCP guidelines suggest a . Comparison of Cervical Cancer Screening Guidelines. Co-testing is preferable to using a Pap test alone for women ages 30– 1 ACS, ASCCP, & ASCP guidelines update In March

Author: Doum Douran
Country: Bulgaria
Language: English (Spanish)
Genre: Literature
Published (Last): 12 August 2015
Pages: 194
PDF File Size: 20.22 Mb
ePub File Size: 18.8 Mb
ISBN: 868-1-70932-864-1
Downloads: 22306
Price: Free* [*Free Regsitration Required]
Uploader: Taum

Thank you Your feedback has been sent. As a private, voluntary, nonprofit membership organization of more than 58, members, ACOG strongly advocates for quality health care for women, maintains the highest standards of clinical practice and continuing education of its members, promotes patient education, and increases awareness among its members and the public of the changing issues facing women’s health care.

A Decision Analysis for the U. How do I access the new guidelines? The new USPSTF recommendations emphasize that the choice of screening strategy should consider the balance of benefit disease detection and potential harms more frequent follow-up testing, invasive diagnostic procedures, and unnecessary treatment in women with false-positive results and involve shared decision making between patients and their health care providers.

For women years of age, routine screening with cytology in 3 years is indicated. CA Cancer J Clin. The potential harm outweighs the small potential benefit of screening women in this age group. However, expert guidelines recommend that for these women, co-testing with cervical cytology and hrHPV testing every 5 years is preferred, screening with cervical cytology alone every 3 years is acceptable, and hrHPV testing alone can be considered as an alternative screening strategy 4.

Now, providers who use cotesting will be receiving combinations of results, some of which will be discordant e. ASCCP convened a steering committee and invited representatives from national professional organizations, government agencies, and advocacy organizations to participate in guidelines development. Cervical cancer screening among women without a cervix. When CIN2,3, not otherwise differentiated, is found in young women, observation or treatment is acceptable.


ACS/ASCCP/ASCP Guidelines for the Early Detection of Cervical Cancer

New research shows lower risk of existing abnormalities than previously thought and provides guidance on use of HPV testing. This varies by age: When CIN3 is found in women of any age, treatment is recommended.

There is no role for testing for low-risk genotypes, and tests for low-risk HPV should not be performed. Cervical Cancer Screening Update.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: Good Stewardship Working Group. For women 21 to 29 years of age, the new guidelines recommend screening with cytology alone every three years. Therefore, women with abnormalities need more intensive follow-up.

A Practice Advisory is issued when information on an emergent clinical issue e. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Despite this, more than 10 million women continue to have this unnecessary screening. A Practice Advisory is issued only online for Fellows but may also be used by patients and the media.

See My Options close. Overtreatment leads to net harm in young women. ACOG does not guarantee, warrant, or endorse the products or ser vices of any firm, organization, or person. This suggests that less aggressive assessment will minimize potential harms of managing abnormalities likely to resolve spontaneously.

In general, cytology should be repeated in months. While their use is not required, clinicians electing to use genotyping need guidance on when to use and how to interpret these tests and how results affect management. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology.


Data analysis shows that women ages are at low risk for invasive cervical cancer, but high risk for HPV exposure and Guideliness lesions. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Address correspondence to Patricia L. Android, iPhone, iPad, Spanish Language.

Guidelines – ASCCP

Reprints are not available from the authors. The guidelines are based on a systematic evidence review. Women with similar risks should be managed similarly. Because the KPNC follow up of patients covers less than 10 years, more time will be needed to see guidelnes these women can return to routine screening after multiple negative follow-up tests. Screening for cervical cancer: Abnormal vaginal cytology is seldom of clinical importance.

If colposcopy is inadequate, diagnostic excision is recommended. Earn up to 6 CME credits per issue.

The major change from guidekines USPSTF guidelines is that for average-risk women aged 30—65 years, the USPSTF now recommends high-risk human papillomavirus hrHPV testing alone every 5 years as an alternative to screening with cervical cytology alone every 3 years or screening with a combination of cytology and hrHPV testing every 5 years.

It is not intended to substitute for the independent professional judgment of the treating clinician.


To see the full article, log in or purchase access. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. How were the new guidelines developed?

Related Posts